drugset / Trial / NCT04715750
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
NaSingle-groupOpen-labelDiagnostic
Summary
This is an open-label study without randomisation. All eligible patients will receive two administrations of the investigational imaging agent \[18F\]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg tracer mass dose), another one with low specific activity (40-50 µg tracer mass dose).
Timeline
- Start
- 2020-11-12
- Primary completion
- 2022-10-26
- Completion
- 2022-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]PI-2620 | Diagnostic / imaging agent | 5 ug | Intravenous |
| Subject | [18F]PI-2620 | Diagnostic / imaging agent | 40 ug | Intravenous |
| Subject | [18F]PI-2620 | Diagnostic / imaging agent | 50 ug | Intravenous |
| Subject | [18F]PI-2620 | Diagnostic / imaging agent | 185 mbq | Intravenous |